Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VRT106 in Combination With Radiotherapy in Adult Patients With DMG/DIPG
NCT07589257Phase 2Recruiting
- Sponsor
- Guangzhou Virotech Pharmaceutical
- Start
- May 2026
- Primary completion
- Jun 2028
- Modality
- Oncolytic Viruses
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of VRT-106 in diffuse midline glioma (DMG) and diffuse intrinsic pontine glioma (DIPG), sponsored by Guangzhou Virotech Pharmaceutical. Primary endpoint: Disease Control Rate at 2 years. Started May 2026; status: recruiting.
02
Drugs
VRT-106
03
Conditions
diffuse midline glioma (DMG)diffuse intrinsic pontine glioma (DIPG)
Beyond the preview
Go deeper on NCT07589257.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07589257.